Midpoint Transverse Process to Pleura (MTP) Block vs Erector Spinae Plane (ESP) Block for Acute Herpes Zoster (HZ) Pain

NCT07732556 | Recruiting

• 1 other identifier: 36265MS150/6/26
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to compare the analgesic efficacy and safety of ultrasound-guided midpoint transverse process block versus ultrasound-guided erector spinae plane block in patients suffering from thoracic herpes zoster pain.

Conditions

Midpoint Transverse Process to Pleura Block; Erector Spinae Plane Block; Acute Herpes Zoster; Pain

Outcome Measures

Primary Outcomes (1)

• Incidence of post-herpatic neuralgia

  Incidence of post-herpatic neuralgia will be recorded after 12 weeks of block

  After 12 weeks of block

Secondary Outcomes (9)

• Blood pressure

  24 hours postoperatively

• Heart rate

  24 hours postoperatively

• Oxygen saturation

  24 hours postoperatively

• Time to first rescue analgesia

  24 hours postoperatively

• Total rescue analgesics consumption

  24 hours postoperatively

Study Arms (2)

Group MTP

OTHER

Patients will receive ultrasound-guided midpoint transverse process to pleura block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone.

Other: Midpoint transverse process to pleura block

Group ESP

OTHER

Patients will receive ultrasound -guided erector spinae plane block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone.

Other: Erector spinae plane block

Interventions

Midpoint transverse process to pleura block OTHER

Patients will receive ultrasound-guided midpoint transverse process to pleura block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone.

Group MTP

Erector spinae plane block OTHER

Patients will receive ultrasound -guided erector spinae plane block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone.

Group ESP

Eligibility Criteria

• Age: 21 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Age 21-60 years.
• Both sexes.
• American Society of Anesthesiologists (ASA) physical status I-II.
• Acute thoracic herpes zoster within 30 days of rash onset.
• Moderate to severe pain \[numeric rating scale (NRS)≥4\].

You may not qualify if:

• Refusal to participate.
• Coagulopathy or anticoagulant therapy.
• Infection at puncture site.
• Allergy to study drugs.
• Severe psychiatric illness or inability to assess pain.
• Previous thoracic surgery deformity.
• Uncontrolled Diabetic patient.
• Chronic diseases as renal, hepatic, malignancy.
• Patients with chronic disease need analgesia.
• Patients are coming for more than 3 months (after healing of rash).

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, El-Gharbia, 31527, Egypt

RECRUITING

MeSH Terms

Conditions

Pain

Condition Hierarchy (Ancestors)

Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Mohamed A Kazamel, MBBCH

CONTACT

00201205997183; mohamed198330_pg@med.tanta.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident of Anesthesia, Intensive Care and Pain Management, Tanta University, Egypt.

Study Record Dates

• First Submitted: July 23, 2026
• First Posted: July 29, 2026
• Study Start: July 1, 2026
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): June 1, 2027
• Last Updated: July 29, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)